🧾 What This Document Is

This is a DEFA14A, a type of SEC filing used for "definitive additional materials." Think of it as an official add-on to a main proxy statement. In this case, it's an internal FAQ document for Centessa Pharmaceuticals employees, explaining the company's acquisition by Eli Lilly and answering their immediate questions. It's not the formal legal agreement, but a communication to keep everyone informed.

🤝 The Deal: What Was Announced

Centessa has agreed to be acquired by the pharmaceutical giant Eli Lilly.

• The Price: Each shareholder will get $38.00 per share in cash right away.
• The "Plus": On top of the cash, each share gets one Contingent Value Right (CVR). These CVRs could pay out up to $9.00 per share in the future if certain drug development milestones are met.
• The Total Potential Value: Combining the upfront cash and the maximum CVR payout, the total potential deal value is approximately $7.8 billion.
• The Premium: The $38.00 cash offer is a 40.5% premium over Centessa's average stock price in the 30 days before the announcement.

👉 Why it matters for shareholders: This deal structure provides a large, certain payout today while also letting them benefit from future success if Centessa's key drugs succeed.

🔮 How the CVR Works

A Contingent Value Right (CVR) is like an IOU for future payments. It's used when a company's value is tied to uncertain future events, like drug approvals.

• For Centessa, the CVRs are tied to regulatory milestones for their orexin 2 receptor agonist drug candidates.
• If those drugs hit specific regulatory targets (like FDA approval), the CVR holders could receive up to three separate payments, totaling up to $9.00 per share.

👉 Why it matters: It allows Lilly to acquire Centessa now while sharing the risk and reward of the most uncertain (but potentially valuable) part of its pipeline with the original shareholders.

⏳ The Timeline and What Happens Next

The deal is not final yet. Here’s the expected path:

• Expected Close: The third quarter of 2026.
• Key Hurdles: The deal needs approval from Centessa shareholders, a sanction from the High Court of Justice in England & Wales, and standard regulatory approvals.
• Until Close: Centessa and Lilly remain completely separate companies. It's "business as usual" for employees.

👥 Impact on Centessa Employees

The FAQ spends significant time addressing employee concerns about job security, pay, and culture.

• Jobs & Hiring: Leaders say no decisions on changes will happen before closing. The company will continue filling key roles from its 2026 plan.
• Compensation & Equity: The big news is for employees with stock grants. All vesting will be accelerated upon closing (if you're still employed). Your options and RSUs will convert into the right to receive the $38.00 cash + one CVR.
• Culture & Systems: For now, nothing changes—remote work policies, HR systems, and performance goals remain as they are. Integration planning will begin with teams from both companies.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths: A significant premium for shareholders, a clear path to monetize Centessa's science, and the resources of a major pharma company (Lilly) to advance the drugs. For employees, it's validation of their work and potential opportunities in a larger organization.
• ⚠️ Risks: The deal could still fall apart if conditions aren't met. Employees face uncertainty about their long-term roles post-integration. The CVR payments are not guaranteed—they depend on future drug development success, which is inherently risky.

🧠 The Analogy

Imagine a talented chef (Centessa) has invented a few promising, complex new recipes (the orexin drugs). A famous, well-equipped restaurant chain (Eli Lilly) offers to buy the chef's small restaurant. The deal pays the chef a lot of money upfront plus gives the chef a "royalty ticket" for each recipe. If those recipes become hit menu items approved by the health department (regulatory milestones), the chef gets extra payments. The chef's staff keep their jobs for now and are told the big chain's kitchen will let them cook for many more people.

📇 Key Contacts & People

For inquiries, the document directs employees and investors to the following contact:

• Investor Relations: Kristen Sheppard, SVP of Investor Relations
• Investor Email: [email protected]

(Note: More detailed contact lists for company directors and officers would be found in the referenced 10-K and proxy statements filed with the SEC.)

🧩 Final Takeaway

Centessa is being acquired by Eli Lilly in a deal valued up to $7.8 billion, offering a 40.5% premium in cash upfront plus a chance for more money later. While the deal awaits approvals, it's business as usual for the company, with accelerated equity vesting being a key benefit for staying until the close.